Market Overview:
The global disease-modifying antirheumatic drug market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as the increasing prevalence of rheumatoid arthritis, technological advancements in the field of DMARDs, and rising demand for biologic DMARDs. However, patent expiries of blockbuster drugs and stringent regulatory approvals are restraining the growth of this market. Based on type, non-steroidal anti-inflammatory drugs (NSAIDs) held a major share of the global disease-modifying antirheumatic drug market in 2017. This segment is projected to grow at a CAGR of 7% during the forecast period owing to its high usage rates for treating various forms of arthritis including rheumatoid arthritis (RA). Steroidal anti-inflammatory drugs (SAIDs) are also expected to witness significant growth during the forecast period due their ability to provide relief from pain and inflammation associated with RA. By application, pharmaceutical industry held a dominant share in 2017 and is projected grow at a CAGR 6%. This can be attributed growing number os therapies available for treatment o RA patients coupled with rising demand for better quality healthcare services across globe .
Product Definition:
A disease-modifying antirheumatic drug (DMARD) is a medication used to treat rheumatoid arthritis (RA), psoriatic arthritis, and other autoimmune diseases. DMARDs slow the progression of the disease by suppressing the immune system.
Non-Steroidal Anti-Inflammatory Drugs:
Non-steroidal anti-inflammatory drugs (NSAIDs) are used to reduce the inflammation associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and other autoimmune diseases. The global market for NSAIDs is expected to grow at a CAGR of XX% from 2016 to 2024.
Steroidal Anti-Inflammatory Drugs:
Steroidal anti-inflammatory drugs are used to reduce swelling, inhibit the production of inflammatory mediators, and provide pain relief. Disease-modifying antirheumatic drug (DMARD) is a type of medication used for the treatment of rheumatoid arthritis and osteoarthritis. DMARDs are often considered as first line therapy due to their ability to reduce joint inflammation without causing any serious side effects unlike other conventional drugs available for the disease condition.
Application Insights:
The other application segment includes use in organ transplantation, periodontology, and others. The other applications of these drugs are limited to few countries due to which the disease-modifying antirheumatic drug market is dominated by the pharmaceutical industry in North America and Europe. In 2017, pharmaceutical industry held a revenue share of around 60% for DDAr while hospital & clinic held 40% share DDAr market revenue.
The hospital and clinic sector is expected to be one of the fastest growing sectors owing to increasing prevalence of rheumatoid arthritis as well as osteoarthritis across regions coupled with rising geriatric population that is more susceptible towards this disorder. As per World Health Organization (WHO), an estimated 1 billion people aged 15 or above suffer from some form of arthritis making it one of the most common diseases globally affecting nearly 5%.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of rheumatology clinics and high disease prevalence are some factors that can be attributed to this dominance. In addition, the availability of highly advanced healthcare infrastructure and relatively higher patient disposable income levels are also expected to contribute toward regional growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income levels, improving economic conditions, expanding middle-class population base along with increasing healthcare expenditure levels in emerging countries such as China and India. Moreover, growing investments by major multinational pharmaceutical companies for commercializing branded drugs at lower prices will further boost revenue generation capacity within this region during the estimated time span from 2018 to 2030 (Ref: 4).
Growth Factors:
- Increasing incidence of autoimmune diseases: The global incidence of autoimmune diseases is increasing at a rapid pace. This is primarily attributed to the changing lifestyle and environmental factors. DMARDs are effective in treating autoimmune diseases and this is expected to drive the market growth over the forecast period.
- Rising awareness about DMARDs: There is a growing awareness among patients about the benefits of using DMARDs for treating various types of arthritis such as rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis (JIA). This is likely to boost demand for these drugs in the coming years.
- Technological advancements in DMARDs: The pharmaceutical companies are investing heavily in R&D activities to develop novel and more efficacious DMARDS with fewer side effects. This will help them capture a larger share of the disease-modifying antirheumatic drug market over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Disease-Modifying Antirheumatic Drug Market Research Report
By Type
Non-Steroidal Anti-Inflammatory Drugs, Steroidal Anti-Inflammatory Drugs, Slow Acting Drug, Immunological Preparation
By Application
Pharmaceutical Industry, Hospital and Clinic, Other
By Companies
AbbVie, Amgen, Pfizer, Roche Holding AG, Novartis International AG, Johnson & Johnson, Bristol-Myers Squibb, Merck, UCB S.A., Eli Lilly and Company
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Disease-Modifying Antirheumatic Drug Market Report Segments:
The global Disease-Modifying Antirheumatic Drug market is segmented on the basis of:
Types
Non-Steroidal Anti-Inflammatory Drugs, Steroidal Anti-Inflammatory Drugs, Slow Acting Drug, Immunological Preparation
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pharmaceutical Industry, Hospital and Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Amgen
- Pfizer
- Roche Holding AG
- Novartis International AG
- Johnson & Johnson
- Bristol-Myers Squibb
- Merck
- UCB S.A.
- Eli Lilly and Company
Highlights of The Disease-Modifying Antirheumatic Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Non-Steroidal Anti-Inflammatory Drugs
- Steroidal Anti-Inflammatory Drugs
- Slow Acting Drug
- Immunological Preparation
- By Application:
- Pharmaceutical Industry
- Hospital and Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Disease-Modifying Antirheumatic Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Disease-modifying antirheumatic drugs (DMARDs) are medications used to treat rheumatoid arthritis, an autoimmune disease. DMARDs work by modifying the body's immune response to the disease.
Some of the major players in the disease-modifying antirheumatic drug market are AbbVie, Amgen, Pfizer, Roche Holding AG, Novartis International AG, Johnson & Johnson, Bristol-Myers Squibb, Merck, UCB S.A., Eli Lilly and Company.
The disease-modifying antirheumatic drug market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Disease-Modifying Antirheumatic Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Disease-Modifying Antirheumatic Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Disease-Modifying Antirheumatic Drug Market - Supply Chain
4.5. Global Disease-Modifying Antirheumatic Drug Market Forecast
4.5.1. Disease-Modifying Antirheumatic Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Disease-Modifying Antirheumatic Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Disease-Modifying Antirheumatic Drug Market Absolute $ Opportunity
5. Global Disease-Modifying Antirheumatic Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Type
5.3.1. Non-Steroidal Anti-Inflammatory Drugs
5.3.2. Steroidal Anti-Inflammatory Drugs
5.3.3. Slow Acting Drug
5.3.4. Immunological Preparation
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Disease-Modifying Antirheumatic Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Application
6.3.1. Pharmaceutical Industry
6.3.2. Hospital and Clinic
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Disease-Modifying Antirheumatic Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Disease-Modifying Antirheumatic Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Disease-Modifying Antirheumatic Drug Demand Share Forecast, 2019-2026
9. North America Disease-Modifying Antirheumatic Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Application
9.4.1. Pharmaceutical Industry
9.4.2. Hospital and Clinic
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Type
9.7.1. Non-Steroidal Anti-Inflammatory Drugs
9.7.2. Steroidal Anti-Inflammatory Drugs
9.7.3. Slow Acting Drug
9.7.4. Immunological Preparation
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Disease-Modifying Antirheumatic Drug Demand Share Forecast, 2019-2026
10. Latin America Disease-Modifying Antirheumatic Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Application
10.4.1. Pharmaceutical Industry
10.4.2. Hospital and Clinic
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Type
10.7.1. Non-Steroidal Anti-Inflammatory Drugs
10.7.2. Steroidal Anti-Inflammatory Drugs
10.7.3. Slow Acting Drug
10.7.4. Immunological Preparation
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Disease-Modifying Antirheumatic Drug Demand Share Forecast, 2019-2026
11. Europe Disease-Modifying Antirheumatic Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Application
11.4.1. Pharmaceutical Industry
11.4.2. Hospital and Clinic
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Type
11.7.1. Non-SteroidalAnti-Inflammatory Drugs
11.7.2. Steroidal Anti-Inflammatory Drugs
11.7.3. Slow Acting Drug
11.7.4. Immunological Preparation
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Disease-Modifying Antirheumatic Drug Demand Share, 2019-2026
12. Asia Pacific Disease-Modifying Antirheumatic Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Application
12.4.1. Pharmaceutical Industry
12.4.2. Hospital and Clinic
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Type
12.7.1. Non-Steroidal Anti-Inflammatory Drugs
12.7.2. Steroidal Anti-Inflammatory Drugs
12.7.3. Slow Acting Drug
12.7.4. Immunological Preparation
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Disease-Modifying Antirheumatic Drug Demand Share, 2019-2026
13. Middle East & Africa Disease-Modifying Antirheumatic Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Application
13.4.1. Pharmaceutical Industry
13.4.2. Hospital and Clinic
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Disease-Modifying Antirheumatic Drug Market Size and Volume Forecast by Type
13.7.1. Non-Steroidal Anti-Inflammatory Drugs
13.7.2. Steroidal Anti-Inflammatory Drugs
13.7.3. Slow Acting Drug
13.7.4. Immunological Preparation
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Disease-Modifying Antirheumatic Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Disease-Modifying Antirheumatic Drug Market: Market Share Analysis
14.2. Disease-Modifying Antirheumatic Drug Distributors and Customers
14.3. Disease-Modifying Antirheumatic Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AbbVie
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Amgen
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Roche Holding AG
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Novartis International AG
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Johnson & Johnson
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Bristol-Myers Squibb
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Merck
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. UCB S.A.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Eli Lilly and Company
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
